Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The third quarter showed business recovery, with promising growth expected in the blood glucose management segment. The company has successfully scaled production of insulin injection pens and is advancing its proprietary "Meihao Pen" technology. Additionally, the company’s CGM component products have entered mass production [7][6] - The company’s revenue for Q3 2025 reached 462 million yuan, a year-on-year increase of 2.56%, while the net profit attributable to shareholders was 93.9 million yuan, up 5.89% year-on-year. For the first three quarters of 2025, revenue totaled 1.194 billion yuan, a 3.28% increase, but net profit fell by 19.25% [7] - The company is expanding its international presence with a production base in Malaysia, which is expected to enhance its capacity and service overseas clients [7] Financial Performance Summary - Revenue projections for 2025-2027 are 1.800 billion yuan, 2.122 billion yuan, and 2.500 billion yuan respectively, with corresponding net profits of 379 million yuan, 449 million yuan, and 539 million yuan [7][6] - The company’s earnings per share (EPS) for 2025 is estimated at 0.67 yuan, with a price-to-earnings (PE) ratio of 33.6 [6][8] - The return on equity (ROE) is projected to be 9.9% in 2025, increasing to 11.4% by 2027 [6][8]
美好医疗（301363）：三季度业务恢复，血糖业务增长可期